Navigation Links
Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
Date:6/1/2009

so presented(3) . Fifty-six patients were enrolled with daily oral doses of AT-101 given for 21 of 28 days in repeated cycles. The treatment was well tolerated, with a low incidence of serious adverse events and no unique central nervous system toxicities. Responses were evaluated in 43 patients and included one confirmed partial response and 8 patients with stable disease, representing half of the patients still alive at the time of analysis. Progression-free survival (PFS) in these patients ranged from 8 to 13 months. Determination of the impact of AT-101 on overall survival (OS), the primary endpoint, is ongoing.

AT-101 in Lung Cancer

Reports from two studies in lung cancer also showed promising signals of antitumor effect. The first presentation described results from a randomized, double-blind, placebo-controlled Phase II trial in 105 patients who had received one prior chemotherapy regimen for non-small cell lung cancer (NSCLC)(4). While the primary endpoint, a statistically significant improvement in PFS, was not met, the docetaxel plus AT-101 arm demonstrated a positive trend in OS, as reflected in the Kaplan-Meier curves (hazard ratio 0.82). This group also demonstrated a 33 percent increase in median survival and a 34 percent increase in 6-month survival compared to the docetaxel plus placebo arm. Common adverse events included fatigue (18 percent), anemia (18 percent) and dyspnea (18 percent). Using NSCLC cell lines, a genomic profile predicting response to AT-101 was developed in collaboration with Duke University. Opportunities to validate this biomarker will be pursued in future trials.

The second presentation reported on an open-label, Phase I/II study of AT-101 in combination with topotecan in patients with relapsed or refractory small cell lung cancer (SCLC) who had received prior platinum-based first line chemotherapy(5). The Phase II portion of the trial included 25 patients div
'/>"/>

SOURCE Ascenta Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
4. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
7. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
8. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
9. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
11. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015 Ale Gicqueau, Founder and ... of Clinical Affairs at Align Technology, on “ Conducting ... upcoming ACRP 2015 Global Conference and Exhibition on April ... , During the poster presentation, Ale Gicqueau and ... running a Postmarket Registry, the requirements and resources to ...
(Date:3/25/2015)... ROCKVILLE, Md. , March 25, 2015 ... for the Vaccine Industry Excellence (ViE) Award "Best Clinical ... second consecutive year that Optimal has been selected as ... World Vaccine Congress, receiving a "Highly Recommended" distinction in ... generate recognition of the efforts, accomplishments, and positive contributions ...
(Date:3/25/2015)... and REYKJAVIK, Iceland , March 25, ... using the genome to create better medicine, today congratulated the ... studies of whole-genome data yet undertaken. The ... – are built around the most comprehensive population-wide ... of deCODE scientists led by Kari Stefansson , deCODE,s ...
(Date:3/25/2015)... MN (PRWEB) March 25, 2015 ... breakthrough in nanoparticle technology that will enable broader ... many other diseases with a simple breath screen. ... on the U.S. Food and Drug Administration (FDA) ... launch of the innovative Nanoparticle Biomarker Tagging device. ...
Breaking Biology Technology:Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3
... - The technological march has added so much complexity ... its promised benefits. , ,That according to John Swainson, ... delivered the opening keynote address at the 2007 ... to help bridge the relationship between business and information ...
... Wis. - The prospect of e-discovery and the possibility - ... any chief executive reach for antacids, but if the CEO's top ... of heartburn can be avoided. , ,That was the message of ... Best & Friedrich , who told a Fusion 2007 gathering that ...
... deal that will bring asset-tracking solutions to healthcare and ... a joint sales and marketing agreement with PanGo ... systems, technology, and services to buildings - including more ... the agreement will expand its wireless capabilities and provide ...
Cached Biology Technology:Fusion 2007: CA chief says IT complexity raises risk 2Fusion 2007: CA chief says IT complexity raises risk 3Fusion 2007: In e-legalities, CIOs and lawyers combine to provide business value 2Fusion 2007: In e-legalities, CIOs and lawyers combine to provide business value 3
(Date:3/17/2015)... , March 17, 2015 MedNet ... specializing in clinical study management systems, is pleased ... attendance at ARENA,s Outsourcing in Clinical Trials Southeast ... event provides an excellent forum for MedNet to ... and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/12/2015)... N.C. , March 12, 2015 The ... at Brenner Children,s Hospital, part of Wake Forest Baptist ... outreach initiative for the 2015 ACC Men,s Basketball Tournament. ... pictures with them and getting their autographs. ... Forest Baptist. It is the only children,s hospital in ...
(Date:3/10/2015)... NEW YORK , March 10, 2015  Continuing ... and the Unexpected, Hammacher Schlemmer introduces The Eye ... user,s identity before granting access to secure websites or ... trusted to verify travelers at international borders, the device ... 240 distinctive pattern points of the iris, converting them ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
... landmark genetic study has identified multiple genes linked to ... disease that affects an estimated 1.4 million Americans. ... brain and blood and occurs in about 31 out ... likely than men to develop the condition, which is ...
... from the January issue of Mayo Clinic Proceedings include ... workplace drug screening and the safety and effectiveness of ... Examine the Effect of Antioxidant Supplements on Cancer ... cancer and deaths related to cancer? Thats a question ...
... The National Academy of Sciences, Sackler Colloquium series ... These networks represent the genomic program for ... cell types. The meeting will focus on ... early embryonic development; gene networks later developmental processes; ...
Cached Biology News:Steps toward Stopping Autoimmune Disease 2Mayo Clinic Proceedings January tip sheet 2Mayo Clinic Proceedings January tip sheet 3
...
MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
Supplemental reagent for annexin V assay....
Large-fragment, single-stranded carrier DNA of the highest quality, perfectly suited for all types of yeast transformation....
Biology Products: